Table 2 Demographic of cohort population.

From: Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer’s dementia using OMOP CDM

Anti-dementia drugs

Cohort population

n (%)*

Female, n (%)

Mean age at drug exposure, year (SD)

Observation time, year (SD)

Donepezil

4218 (48.75)

2769 (65.6)

77.0 (8.0)

4.4 (2.3)

Rivastigmine

777 (8.98)

499 (64.2)

66.0 (7.5)

4.5 (2.4)

Galantamine

494 (5.71)

278 (56.3)

73.6 (9.0)

6.3 (3.0)

Memantine

1565 (18.09)

1042 (66.6)

76.3 (9.0)

4.4 (2.2)

Total AD

8653† (100)

5569 (64.4)

76.4 (8.2)

4.6 (2.4)

  1. n indicates the number of subjects. *Percent values indicate the number of anti-dementia medications over total number of firstly diagnosed as Alzheimer’s dementia (AD). †Total number of AD subjects are not equal to the sum of each drug because there are AD patients without any medications such as N-methyl-d-aspartate (NMDA) receptor antagonist (e.g. Memantine) and cholinesterase inhibitors (AChEIs) (e.g. Donepezil, Rivastigmine and Galantamine). The anti-dementia drugs were prescribed within 6 months after diagnosis of AD and initial dual therapy between AChEIs and memantine was possible.
Back to article page